SIONSionna Therapeutics, Inc.

Healthcare
$51.04+193% 1Y

Price

+193%1Y

End-of-day closes, not the intraday tick.

The five questions

2 of 5 available

Only two of the five can be answered for SION today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Watch
What they do

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/En/a
Market value$1.93B
1 year+193%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 4, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 14, 2026On September 9, 2026, the Board of Directors (the “Board”) of Sionna Therapeutics, Inc. (the “Company”) approved a restructuring plan (the “Restructuring”) intended to focus its resources on advancing the Company’s SION-451 and SION-2222 dual combination program and extend the Company’s cash runway.Exit or disposal costs (restructuring) · Form 8-K
  2. Aug 10, 2026On August 10, 2026, Sionna Therapeutics, Inc., or the Company, announced topline data from both its PreciSION CF Phase 2a proof-of-concept trial of SION-719 when added to current standard of care and its Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

The closest names by size in the same industry

Compare peers
VRDN+1.7%
Viridian Therapeutics, Inc.
PVLA+5.7%
Palvella Therapeutics, Inc.
LKFT+0.78%
Lakefront Biotherapeutics NV
PGEN+3.0%
Precigen, Inc.
STOK+3.3%
Stoke Therapeutics, Inc.
HRMY+1.7%
Harmony Biosciences Holdings, Inc.